Pieris Pharmaceuticals, Inc.:
Platform technology company developing Anticalins (engineered lipocalin proteins) for oncology and respiratory diseases. 2H18 Phase 1 data for: 1) fully-proprietary IO program PRS-343 for HER2+ solid tumors (targeting 4-1BB) and 2) AZN-partnered PRS-060 for moderate-to-severe asthma (targeting IL4RA through inhalation). I-O partnerships w Seattle Genetics and Servier.
255 State Street
Boston, MA 02109
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by